India’s Cipla gets U.S. beachhead with $550M deal for 2 generics operations

Eric Palmer

India's has lagged behind its compatriots in challenging drugmakers on their own turf, currently getting less than 10% of its revenues from the lucrative market. The company is making moves to change that equation, announcing a small on Friday to buy two U.S. focused companies.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS